Published finding — does the expert body still believe it?
The EMPEROR-Reduced trial's stated primary conclusion — Empagliflozin reduces cardiovascular death or heart-failure hospitalization in HFrEF regardless of diabetes status. — replicates in independent cohorts.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al. · New England Journal of Medicine · 2020
· openalex W3081830235
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0497
The DAPA-HF trial's stated primary conclusion — Dapagliflozin reduces heart-failure worsening and CV death in HFrEF with or without diabetes. — replicates in independent cohorts.
0.1026
The cardiovascular benefit of dapagliflozin in HFrEF patients is independent of the presence or absence of type 2 diabetes, suggesting glucose-independent mechanisms of action.
0.1039
SGLT2 inhibitor class benefits observed in type 2 diabetes cardiovascular outcome trials will generalize to the broader HFrEF population, including patients without diabetes.
0.1061
Dapagliflozin 10 mg once daily reduces the composite of worsening heart failure or cardiovascular death (HR 0.74; 95% CI 0.65–0.85) compared to placebo in patients with HFrEF (EF ≤40%), regardless of diabetes status.
0.1101
Dapagliflozin reduces cardiovascular mortality (HR 0.82; 95% CI 0.69–0.98) in patients with HFrEF compared to placebo.
0.1136
Dapagliflozin reduces the risk of a first worsening heart failure event (HR 0.70; 95% CI 0.59–0.83) in patients with HFrEF compared to placebo.